Featured News
COMPANY
Virginia Catalyst Awards $2 Million in Grants to Support Life Sciences in the Commonwealth
The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it has awarded $2 million in grants to four life and bioscience projects in the Commonwealth of Virginia, pending execution of the grant agreements.
Virginia Catalyst announces Grant Round 14 awarded projects
The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it has awarded $2 million in grants to four life and bioscience projects in the Commonwealth of Virginia, pending execution of the grant agreements.
CBIC announces award recipients
CLICK TO VIEW ORIGINAL ARTICLE > ALBEMARLE COUNTY, Va. (CBS19 NEWS) --Â The Charlottesville Business Innovation Council recently recognized its annual award recipients at its gala. These awards go to local businesses, start-ups, leaders and others who have had an...
CBIC of Virginia Names AMPEL BioSolutions as Innovator-of-Year
CLICK TO VIEW ARTICLE> Charlottesville, VA - June 2, 2023 - The Charlottesville Business Innovation Council (CBIC) has awarded AMPEL BioSolutions, a leading data science company, with the prestigious "Innovator-of-Year" title. The recognition was given to AMPEL...
PLATFORM
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
PRODUCTS
AMPEL BioSolutions’ Breakthrough Predicts Drug Options for Fibromyalgia
The FibroGENE® lab test, only a concept for the last few years, is now ready for development for practical use as a decision support biomarker test that could greatly impact health care by allowing physicians to identify the cause of patient disease symptoms and select appropriate treatment more precisely.Â
AMPEL BioSolutions’ Breakthrough Predicts Drug Options for Fibromyalgia
The FibroGENE® lab test, only a concept for the last few years, is now ready for development for practical use as a decision support biomarker test that could greatly impact health care by allowing physicians to identify the cause of patient disease symptoms and select appropriate treatment more precisely.Â
AMPEL BioSolutions’ Breakthrough Predicts Drug Options for Fibromyalgia
Paired with AMPEL’s pipeline of tools to analyze very large and complex clinical datasets (“Big Data”), FibroGENE® is a significant step towards implementing a routine test for monitoring fibromyalgia and providing decision support for treatment based on a patient’s gene expression. This will transform the way doctors treat fibromyalgia by using the information gathered by the lab test and analyzed by bioinformatics to characterize the precise molecular abnormalities and treat symptoms, reduce pain and increase the quality of life of millions of Americans.Â
AMPEL BioSolutions, Duke Researchers Establish Fibromyalgia Gene Signature
Precision medicine company AMPEL BioSolutions and academic partners at Duke University identified two distinct gene signatures for systemic lupus erythematosus (SLE), one of which appears specific to patients experiencing fibromyalgia.
New Blood Test to Help Physicians Prevent Major Cardiovascular Events in Women with Lupus
Now, a genetic precision medicine test for lupus patients could save lives by predicting heart disease before it happens and providing decision support for prophylactic therapies.
Lupus, coronary artery disease share genetic risk factors; data may lead to early testing
Researchers have identified shared genetic risk factors for systemic lupus erythematosus and coronary artery disease, according to data published in Cell Reports Medicine.
PARTNERS
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.